KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Invested Capital (2016 - 2025)

Historic Invested Capital for Gsk (GSK) over the last 17 years, with Q2 2025 value amounting to $1.8 billion.

  • Gsk's Invested Capital changed N/A to $1.8 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 billion, marking a year-over-year change of. This contributed to the annual value of $63.7 billion for FY2024, which is 126.6% up from last year.
  • Gsk's Invested Capital amounted to $1.8 billion in Q2 2025.
  • Over the past 5 years, Gsk's Invested Capital peaked at $64.0 billion during Q4 2024, and registered a low of $1.8 billion during Q2 2025.
  • Moreover, its 5-year median value for Invested Capital was $32.6 billion (2022), whereas its average is $32.4 billion.
  • As far as peak fluctuations go, Gsk's Invested Capital plummeted by 3068.83% in 2022, and later soared by 9252.17% in 2023.
  • Over the past 5 years, Gsk's Invested Capital (Quarter) stood at $47.0 billion in 2021, then crashed by 30.69% to $32.6 billion in 2022, then skyrocketed by 92.52% to $62.8 billion in 2023, then grew by 1.9% to $64.0 billion in 2024, then plummeted by 97.19% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q2 2025, $64.0 billion for Q4 2024, and $62.8 billion during Q4 2023.